Tactile Medical Expands Launch of Nimbl™ to Include Patients with Lower Extremity Lymphedema
Tactile Medical (NASDAQ: TCMD) has expanded the availability of its Nimbl™ pneumatic compression device to include treatment for lower extremity lymphedema across the United States. This expansion follows the initial October 2024 launch for upper extremity lymphedema treatment.
The Nimbl device represents significant technological advancement, being 68% lighter and 40% smaller than the company's current generation PCD, with 94% less hosing in its lower extremity garment. It is the only basic PCD featuring Bluetooth® connectivity, allowing patients to track treatments and symptoms through the free Kylee™ digital application.
This expansion targets a market of 16 million Americans with chronic swelling in lower extremities, offering them a more portable and user-friendly treatment option designed to improve patient adherence and care experience.
Tactile Medical (NASDAQ: TCMD) ha ampliato la disponibilità del suo dispositivo di compressione pneumatica Nimbl™ per includere il trattamento del linfedema agli arti inferiori in tutto gli Stati Uniti. Questa espansione segue il lancio iniziale di ottobre 2024 per il trattamento del linfedema agli arti superiori.
Il dispositivo Nimbl rappresenta un notevole progresso tecnologico, essendo il 68% più leggero e il 40% più piccolo rispetto alla generazione attuale di PCD dell'azienda, con il 94% di tubazioni in meno nel suo indumento per gli arti inferiori. È l'unico PCD di base dotato di connettività Bluetooth®, che consente ai pazienti di monitorare i trattamenti e i sintomi tramite l'applicazione digitale gratuita Kylee™.
Questa espansione mira a un mercato di 16 milioni di americani con gonfiore cronico agli arti inferiori, offrendo loro un'opzione di trattamento più portatile e user-friendly progettata per migliorare l'aderenza del paziente e l'esperienza di cura.
Tactile Medical (NASDAQ: TCMD) ha ampliado la disponibilidad de su dispositivo de compresión neumática Nimbl™ para incluir el tratamiento del linfedema en las extremidades inferiores en todo Estados Unidos. Esta expansión sigue al lanzamiento inicial de octubre de 2024 para el tratamiento del linfedema en las extremidades superiores.
El dispositivo Nimbl representa un avance tecnológico significativo, siendo 68% más ligero y 40% más pequeño que la generación actual de PCD de la empresa, con 94% menos de mangueras en su prenda para extremidades inferiores. Es el único PCD básico que cuenta con conectividad Bluetooth®, lo que permite a los pacientes rastrear tratamientos y síntomas a través de la aplicación digital gratuita Kylee™.
Esta expansión tiene como objetivo un mercado de 16 millones de estadounidenses con hinchazón crónica en las extremidades inferiores, ofreciéndoles una opción de tratamiento más portátil y fácil de usar diseñada para mejorar la adherencia del paciente y la experiencia de atención.
택타일 메디컬(Tactile Medical) (NASDAQ: TCMD)은 미국 전역에서 하체 림프부종 치료를 위한 닌블(Nimbl™) 공압 압축 장치의 가용성을 확장했습니다. 이번 확장은 상체 림프부종 치료를 위한 2024년 10월의 초기 출시 이후 이루어졌습니다.
닌블 장치는 68% 가볍고 40% 작은 회사의 현재 PCD 세대에 비해 상당한 기술적 발전을 나타내며, 하체 장비에서 94% 적은 호스를 사용합니다. 이는 환자가 무료 디지털 애플리케이션 Kylee™를 통해 치료 및 증상을 추적할 수 있는 유일한 기본 PCD로, Bluetooth® 연결 기능이 있습니다.
이번 확장은 하체에 만성 부종이 있는 1,600만 미국인을 대상으로 하여, 환자의 순응도와 치료 경험을 개선하도록 설계된 보다 휴대 가능한 사용자 친화적인 치료 옵션을 제공합니다.
Tactile Medical (NASDAQ: TCMD) a élargi la disponibilité de son dispositif de compression pneumatique Nimbl™ pour inclure le traitement du lymphœdème des membres inférieurs à travers les États-Unis. Cette expansion fait suite au lancement initial en octobre 2024 pour le traitement du lymphœdème des membres supérieurs.
Le dispositif Nimbl représente une avancée technologique significative, étant 68% plus léger et 40% plus petit que la génération actuelle de PCD de l'entreprise, avec 94% de tuyaux en moins dans son vêtement pour les membres inférieurs. C'est le seul PCD de base doté d'une connectivité Bluetooth®, permettant aux patients de suivre les traitements et les symptômes via l'application numérique gratuite Kylee™.
Cette expansion cible un marché de 16 millions d'Américains souffrant de gonflement chronique des membres inférieurs, leur offrant une option de traitement plus portable et conviviale conçue pour améliorer l'adhésion des patients et l'expérience de soins.
Tactile Medical (NASDAQ: TCMD) hat die Verfügbarkeit seines Nimbl™ pneumatischen Kompressionsgeräts ausgeweitet, um die Behandlung von Lymphödem der unteren Extremitäten in den gesamten USA zu ermöglichen. Diese Erweiterung folgt auf die ursprüngliche Einführung im Oktober 2024 zur Behandlung von Lymphödem der oberen Extremitäten.
Das Nimbl-Gerät stellt einen bedeutenden technologischen Fortschritt dar und ist 68% leichter und 40% kleiner als die aktuelle PCD-Generation des Unternehmens, mit 94% weniger Schlauchmaterial in seinem Bekleidungsstück für die unteren Extremitäten. Es ist das einzige grundlegende PCD, das über Bluetooth®-Konnektivität verfügt, wodurch Patienten ihre Behandlungen und Symptome über die kostenlose digitale Anwendung Kylee™ verfolgen können.
Diese Expansion zielt auf einen Markt von 16 Millionen Amerikanern mit chronischen Schwellungen in den unteren Extremitäten ab und bietet ihnen eine tragbarere und benutzerfreundlichere Behandlungsoption, die darauf ausgelegt ist, die Patientenadhärenz und das Pflegeerlebnis zu verbessern.
- Expanded market reach to 16 million potential patients with lower extremity conditions
- Significant product improvements: 68% lighter, 40% smaller than previous generation
- Unique feature advantage with Bluetooth connectivity and digital tracking app
- Enhanced portability with 94% less hosing in lower extremity garment
- None.
Insights
The expansion of Nimbl to lower extremity lymphedema marks a pivotal development for Tactile Medical, significantly broadening its addressable market from the initial upper extremity focus launched in October 2024. The 16 million Americans affected by lower extremity chronic swelling represents a substantial market opportunity, dwarfing the upper extremity patient population.
The device's technical advantages - 68% lighter, 40% smaller and 94% reduction in hosing - address critical barriers to patient adherence and mobility. These improvements directly target key factors that historically device adoption and regular usage. The unique Bluetooth connectivity with the Kylee™ digital application creates a competitive moat through enhanced patient engagement and data tracking capabilities.
From a market perspective, this expansion positions Tactile Medical to potentially capture a larger share of the pneumatic compression device market through:
- Enhanced patient convenience driving potential market share gains from competitors
- Improved adherence metrics potentially leading to better insurance coverage and reimbursement
- Digital health integration opening doors for value-based care partnerships
- Phased launch strategy allowing for controlled market penetration and operational optimization
The strategic decision to launch upper extremity applications first, followed by the larger lower extremity market, suggests a methodical approach to market development. This allows for refinement of commercial processes and gathering of real-world evidence before addressing the more substantial market opportunity.
Next-Generation Platform Now Available for Both Upper and Lower Extremity Conditions
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl’s expanded availability to include lower extremity conditions (“phlebolymphedema”) follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema.
“On the heels of Nimbl’s launch for patients with upper extremity swelling, we are pleased to now expand access to the 16 million Americans with chronic swelling in the lower extremities,” said Sheri Dodd, Chief Executive Officer at Tactile Medical. “These patients require effective, convenient therapies to help manage their symptoms. With Nimbl, they now have access to a solution which embodies patient-focused innovation and reflects our commitment to serving patients and improving their care experience.”
Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is
“Nimbl for lower extremity lymphedema is intentionally designed as a user-friendly, patient-centric treatment option that is comfortable, clinically effective, and optimized for increased adherence,” said Tony Gasparis, MD, Chief Medical Officer at Tactile Medical. “Its physical dimensions and significant reduction in hose length afford patients the ability to more easily transport Nimbl around the home, or take it with them when traveling, providing an improved all around patient experience.”
About Tactile Systems Technology, Inc. (DBA Tactile Medical)
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Investor Inquiries:
Sam Bentzinger
Gilmartin Group
investorrelations@tactilemedical.com
FAQ
What are the key features of Tactile Medical's new Nimbl device for lymphedema (TCMD)?
When did Tactile Medical (TCMD) expand Nimbl's availability to lower extremity lymphedema?
How many potential patients could benefit from TCMD's Nimbl lower extremity treatment?
What digital capabilities does TCMD's Nimbl device offer for patient monitoring?
